Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern such as Omicron hampered efforts in controlling the ongoing coronavirus disease …

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted
in significant casualties and put immense strain on public health systems worldwide, leading …

Continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7 and BA. 2.75. 2. Here we examine the …

Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued …

SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in
December 2019. Vaccines developed were very effective initially, however, the virus has …

The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly
evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to …

SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS)
antibodies that exist in diverse individuals as public antibody clones. We rationally selected …